High SLC20A1 Expression Is Associated With Poor Prognosis for Radiotherapy of Estrogen Receptor-positive Breast Cancer

Overview

Journal Cancer Diagn Progn

Specialty Oncology

Date 2022 Jul 11

PMID 35813014

Authors

Chotaro Onaga

Shoma Tamori

Izumi Matsuoka

Ayaka Ozaki

Hitomi Motomura

Yuka Nagashima

Tsugumichi Sato

Keiko Sato

Kouji Tahata

Yuyun Xiong

Yoshio Nakano

Yasunari Mano

Satoru Miyazaki

Kazunori Sasaki

Shigeo Ohno

Kazunori Akimoto

Affiliations

Soon will be listed here.

Abstract

Background/aim: Radiotherapy is one of the main treatments for estrogen receptor-positive (ER+) breast cancer. However, in some ER+ breast cancer cases, radiotherapy is insufficient to inhibit progression and there is a lack of markers to predict radiotherapy insensitivity. Solute carrier family 20 member 1 (SLC20A1) is a sodium/inorganic phosphate symporter, which has been proposed to be a viable prognostic marker for luminal A and B types of ER+ breast cancer. The present study examined the possibility of SLC20A1 as a novel biomarker for the prediction of radiotherapy efficiency.

Patients And Methods: The Molecular Taxonomy of Breast Cancer International Consortium dataset was downloaded from cBioportal and the prognosis of patients with high SLC20A1 expression (SLC20A1 ) was compared with that of patients with low SLC20A1 expression, without or with radiotherapy and tumor stages I, II, and III, using the Kaplan-Meier method and multivariate Cox regression analyses of disease-specific and relapse-free survival.

Results: Patients in the SLC20A1 group with radiotherapy showed poor clinical outcomes in both luminal A and luminal B breast cancers. Furthermore, in luminal A breast cancer at tumor stage I, patients in the SLC20A1 group with radiotherapy also showed poor clinical outcomes. Therefore, these results suggest that radiotherapy is insufficient for patients in the SLC20A1 group for both luminal A and B types, and especially for the luminal A type at tumor stage I.

Conclusion: SLC20A1 can be used as a prognostic marker for the prediction of the efficacy of radiotherapy for luminal A and luminal B breast cancers.

Citing Articles

Co‑expression of and is associated with poor prognosis, and is required for the survival of ALDH1‑positive pancreatic cancer stem cells.

Matsuoka I, Kasai T, Onaga C, Ozaki A, Motomura H, Maemura Y Oncol Lett. 2024; 28(3):426.

PMID: 39021737 PMC: 11253103. DOI: 10.3892/ol.2024.14558.

High Expression Indicates Poor Prognosis in Prostate Cancer.

Okamoto T, Onaga C, Matsuoka I, Ozaki A, Matsuda C, Kasai T Cancer Diagn Progn. 2023; 3(4):439-448.

PMID: 37405223 PMC: 10316049. DOI: 10.21873/cdp.10237.

References

Speers C, Zhao S, Liu M, Bartelink H, Pierce L, Feng F . Development and Validation of a Novel Radiosensitivity Signature in Human Breast Cancer. Clin Cancer Res. 2015; 21(16):3667-77. DOI: 10.1158/1078-0432.CCR-14-2898. View

Sato K, Akimoto K . Expression Levels of KMT2C and SLC20A1 Identified by Information-theoretical Analysis Are Powerful Prognostic Biomarkers in Estrogen Receptor-positive Breast Cancer. Clin Breast Cancer. 2016; 17(3):e135-e142. DOI: 10.1016/j.clbc.2016.11.005. View

Johann S, Gibbons J, OHara B . GLVR1, a receptor for gibbon ape leukemia virus, is homologous to a phosphate permease of Neurospora crassa and is expressed at high levels in the brain and thymus. J Virol. 1992; 66(3):1635-40. PMC: 240899. DOI: 10.1128/JVI.66.3.1635-1640.1992. View

Ng W, Huang Q, Liu X, Zimmerman M, Li F, Li C . Molecular mechanisms involved in tumor repopulation after radiotherapy. Transl Cancer Res. 2015; 2(5):442-448. PMC: 4293635. DOI: 10.3978/j.issn.2218-676X.2013.10.03. View

Clevers H . The cancer stem cell: premises, promises and challenges. Nat Med. 2011; 17(3):313-9. DOI: 10.1038/nm.2304. View

Pan H, Gray R, Braybrooke J, Davies C, Taylor C, McGale P . 20-Year Risks of Breast-Cancer Recurrence after Stopping Endocrine Therapy at 5 Years. N Engl J Med. 2017; 377(19):1836-1846. PMC: 5734609. DOI: 10.1056/NEJMoa1701830. View

Beck L, Leroy C, Beck-Cormier S, Forand A, Salaun C, Paris N . The phosphate transporter PiT1 (Slc20a1) revealed as a new essential gene for mouse liver development. PLoS One. 2010; 5(2):e9148. PMC: 2818845. DOI: 10.1371/journal.pone.0009148. View

Onaga C, Tamori S, Motomura H, Ozaki A, Matsuda C, Matsuoka I . High Expression Is Associated With Poor Prognoses in Claudin-low and Basal-like Breast Cancers. Anticancer Res. 2021; 41(1):43-54. DOI: 10.21873/anticanres.14750. View

van de Vijver M, He Y, Vant Veer L, Dai H, Hart A, Voskuil D . A gene-expression signature as a predictor of survival in breast cancer. N Engl J Med. 2002; 347(25):1999-2009. DOI: 10.1056/NEJMoa021967. View

10.

Sestak I, Dowsett M, Zabaglo L, Lopez-Knowles E, Ferree S, Cowens J . Factors predicting late recurrence for estrogen receptor-positive breast cancer. J Natl Cancer Inst. 2013; 105(19):1504-11. PMC: 3787911. DOI: 10.1093/jnci/djt244. View

11.

Akrami M, Arasteh P, Eghbali T, Raeisi Shahraki H, Tahmasebi S, Zangouri V . Introducing novel and comprehensive models for predicting recurrence in breast cancer using the group LASSO approach: are estimates of early and late recurrence different?. World J Surg Oncol. 2018; 16(1):185. PMC: 6136222. DOI: 10.1186/s12957-018-1489-0. View

12.

Curtis C, Shah S, Chin S, Turashvili G, Rueda O, Dunning M . The genomic and transcriptomic architecture of 2,000 breast tumours reveals novel subgroups. Nature. 2012; 486(7403):346-52. PMC: 3440846. DOI: 10.1038/nature10983. View

13.

Arnst J, Beck Jr G . Modulating phosphate consumption, a novel therapeutic approach for the control of cancer cell proliferation and tumorigenesis. Biochem Pharmacol. 2020; 183:114305. PMC: 9667393. DOI: 10.1016/j.bcp.2020.114305. View

14.

Bushnell G, Deshmukh A, den Hollander P, Luo M, Soundararajan R, Jia D . Breast cancer dormancy: need for clinically relevant models to address current gaps in knowledge. NPJ Breast Cancer. 2021; 7(1):66. PMC: 8163741. DOI: 10.1038/s41523-021-00269-x. View

15.

Maughan K, Lutterbie M, Ham P . Treatment of breast cancer. Am Fam Physician. 2010; 81(11):1339-46. View

16.

Darby S, McGale P, Correa C, Taylor C, Arriagada R, Clarke M . Effect of radiotherapy after breast-conserving surgery on 10-year recurrence and 15-year breast cancer death: meta-analysis of individual patient data for 10,801 women in 17 randomised trials. Lancet. 2011; 378(9804):1707-16. PMC: 3254252. DOI: 10.1016/S0140-6736(11)61629-2. View

17.

Ades F, Zardavas D, Bozovic-Spasojevic I, Pugliano L, Fumagalli D, de Azambuja E . Luminal B breast cancer: molecular characterization, clinical management, and future perspectives. J Clin Oncol. 2014; 32(25):2794-803. DOI: 10.1200/JCO.2013.54.1870. View

18.

Phillips T, McBride W, Pajonk F . The response of CD24(-/low)/CD44+ breast cancer-initiating cells to radiation. J Natl Cancer Inst. 2006; 98(24):1777-85. DOI: 10.1093/jnci/djj495. View

19.

Pereira B, Chin S, Rueda O, Vollan H, Provenzano E, Bardwell H . The somatic mutation profiles of 2,433 breast cancers refines their genomic and transcriptomic landscapes. Nat Commun. 2016; 7:11479. PMC: 4866047. DOI: 10.1038/ncomms11479. View

20.

Davis Jr J, Kirk J, Ji Y, Tang D . Tumor Dormancy and Slow-Cycling Cancer Cells. Adv Exp Med Biol. 2019; 1164:199-206. PMC: 8025565. DOI: 10.1007/978-3-030-22254-3_15. View